Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc (ELTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,604
  • Shares Outstanding, K 17,490
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,900 K
  • EBIT $ -42 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 34.47

Options Overview Details

View History
  • Implied Volatility 419.31% (-105.08%)
  • Historical Volatility 67.51%
  • IV Percentile 89%
  • IV Rank 69.34%
  • IV High 576.32% on 11/20/25
  • IV Low 64.29% on 08/15/25
  • Expected Move (DTE 14) 0.43 (5.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 207
  • Put/Call OI Ratio 10.03
  • Today's Open Interest 7,029
  • Open Int (30-Day) 7,235
  • Expected Range 7.58 to 8.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.47
  • Number of Estimates 1
  • High Estimate -0.47
  • Low Estimate -0.47
  • Prior Year -1.02
  • Growth Rate Est. (year over year) +53.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.43 +7.67%
on 12/02/25
9.55 -16.23%
on 11/28/25
-1.13 (-12.38%)
since 11/05/25
3-Month
7.43 +7.67%
on 12/02/25
12.62 -36.61%
on 09/17/25
-3.48 (-30.31%)
since 09/05/25
52-Week
4.60 +73.91%
on 04/09/25
12.62 -36.61%
on 09/17/25
+3.19 (+66.32%)
since 12/05/24

Most Recent Stories

More News
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 8.00 (-3.90%)
Elicio Therapeutics: Q3 Earnings Snapshot

Elicio Therapeutics: Q3 Earnings Snapshot

ELTX : 8.00 (-3.90%)
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as...

ELTX : 8.00 (-3.90%)
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ...

ELTX : 8.00 (-3.90%)
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 8.00 (-3.90%)
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient population Patients treated with ELI-002 7P...

ELTX : 8.00 (-3.90%)
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant setting Trial is anticipated to begin enrolling in H1’2026 BOSTON,...

ELTX : 8.00 (-3.90%)
Elicio Therapeutics Reports Inducement Grants

BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...

ELTX : 8.00 (-3.90%)
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapy Robust mKRAS-specific T cell responses were observed...

ELTX : 8.00 (-3.90%)
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to...

ELTX : 8.00 (-3.90%)

Business Summary

Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 8.85
2nd Resistance Point 8.65
1st Resistance Point 8.32
Last Price 8.00
1st Support Level 7.80
2nd Support Level 7.60
3rd Support Level 7.27

See More

52-Week High 12.62
Fibonacci 61.8% 9.56
Fibonacci 50% 8.61
Last Price 8.00
Fibonacci 38.2% 7.66
52-Week Low 4.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar